Detection of subclinical trastuzumab-induced cardiotoxicity in patients with breast cancer

Arquivos Brasileiros de Cardiologia

Volumn 101, Issue 1, 2013, Pages 2-3

  dos Santos, Marília Harumi Higuchi ^a  

^a Stomal Therapy Service of the Cancer Institute   (Brazil)

Author keywords

Agents; Antineoplastic; Breast neoplasms; Cardiotoxins; Heart failure; Ventricular dysfunction

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; TRASTUZUMAB; TROPONIN;

BREAST CANCER; CANCER PROGNOSIS; CARDIOTOXICITY; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; VENTRICULAR DYSFUNCTION;

EID: 84881229430     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130143     Document Type: Editorial

References (12)

1. Colombo A, Meroni CA, Cipolla CM, Cardinale D. Managing cardiotoxicity of chemotherapy. Curr Treat Options Cardiovasc Med. 2013. May 16 [Epub ahead of print].
2. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263-70.
3. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of Beta-Adrenoceptor blockade in breast cancer patients undergoing chemotherapy: a follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-6.
4. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042-9.
5. Pellegrino L, Stebbing J, Braga VM, Frampton AE, Jacob J, Buluwela L, et al. miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res. 2013;41(10)5400-5412.
6. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006;114(23):2474-81.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
8. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-8.
9. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.
10. Martín M, Esteva FJ, Alba E, Khandheria B, Pérez-Isla L, García-Sáenz JA, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009;14(1):1-11.
11. Edvardsen T. Can modern echocardiographic techniques predict druginduced cardiotoxicity? J Am Coll Cardiol. 2011;57(22):2271-2.
12. Dores H, Abecasis J, Correia MJ, Gândara F, Fonseca C, Azevedo J, et al. Detecção de Cardiotoxicidade Subclínica Induzida por Trastuzumabe em Portadoras de Câncer de Mama. Arq Bras Cardiol. 2013;100(4):328-32.